Alimera completes $40 million convertible preferred stock sale Alimera Sciences.

Alimera completes $40 million convertible preferred stock sale Alimera Sciences, Inc. , a biopharmaceutical business that specializes in the research, commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it offers finished the sale of $40 million of Series A Convertible Desired Share and warrants to get Series A Preferred to a group of institutional investors, including both new and existing investors, in an exclusive placement. ‘We believe the closing of this financing coupled with our current money position will enable us to proceed with the immediate commercialization of ILUVIEN in Germany, the United France and Kingdom, without needing to raise any extra funds for this purpose,’ said Dan Myers, Alimera’s President and Chief Executive Officer .

Patent No. 8,301,232 for the technology and device. The three colleagues began working on the heart-monitoring gadget in 2008. We believe that mobile ECGs and additional breakthroughs in mobile wellness can significantly change just how medicine is shipped, Dr. Albert said. AliveCor's Heart Monitor is intended for use by licensed doctors to record initially, display, shop, transfer, and assess single-channel electrocardiogram rhythms. The rhythm strips could be of any duration, and are kept on the iPhone and safely in the cloud for later on analysis, sharing and printing through AliveCor's secure internet site.